Avid200, First-In-Class Tgf-Beta 1 And 3 Selective And Potent Inhibitor: Safety And Biomarker Results Of A Phase I Monotherapy Dose-Escalation Study In Patients With Advanced Solid Tumors.

Timothy A Yap,Nehal J. Lakhani,Daniel Vilarim Araujo,Jordi Rodon Ahnert,Sreenivasa R Chandana,Manish Sharma,Jean-François Denis,Tina Gruosso,Gilles Tremblay, Maureen O'Connor,Ria Ghosh, Sandra Sinclair,Debra L. Wood,Paul I. Nadler,Lillian L. Siu

JOURNAL OF CLINICAL ONCOLOGY（2020）

引用 11|浏览38

暂无评分

摘要

3587Background: AVID200 is a rationally designed first-in-class, selective inhibitor of transforming growth factor-beta (TGF-beta) that neutralizes TGF-beta 1 \u0026 3 with pM potency and 4,000 fold sel...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要